10 Best Oncology Apps

Slideshow

Oncologists were among the first practitioners to embrace mobile technologies. We present the top 10 oncology apps for iPhone, iPad, and Android devices.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
Future findings from a translational analysis of the OVATION-2 trial may corroborate prior clinical data with IMNN-001 in advanced ovarian cancer.
The dual high-affinity binding observed with ISB 2001 may avoid resistance mechanisms reported with other BCMA-targeted therapies.
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practices in the breast cancer field.
Related Content
THIO Plus Cemiplimab Associated with Prolonged OS in ICI-Resistant NSCLC

THIO Plus Cemiplimab Associated with Prolonged OS in ICI-Resistant NSCLC

Gina Mauro
June 5th 2025
Article

THIO with cemiplimab is active and well-tolerated in patients with advanced non–small cell lung cancer resistant to immune checkpoint inhibitors in second- and third-line settings.

Sharpening the Prostate Cancer Toolkit: Practical Insights on PSMA Imaging

Sharpening the Prostate Cancer Toolkit: Practical Insights on PSMA Imaging

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Mike Lattanzi, MD;Damian N. Sorce, MD
June 5th 2025
Podcast

Experts weigh in on the practical applications of PSMA PET imaging

ctDNA Analysis Shows Durvalumab/CRT Reduced Progression in Advanced Cervical Cancer

ctDNA Analysis Shows Durvalumab/CRT Reduced Progression in Advanced Cervical Cancer

Ashley Chan
June 5th 2025
Article

The risk of progression was reduced with the use of durvalumab/CRT for advanced cervical cancer, according to an exploratory ctDNA analysis.

Professor of Pharmacology, Eric Winer, MD, spoke about a publication he authored exploring the state of oncologist burnout and how it impacts practice.

Exploring Burnout Causes and Management in Oncologic Practice

Eric P. Winer, MD
June 2nd 2025
Podcast

Professor of Pharmacology, Eric Winer, MD, spoke about a publication he authored exploring the state of oncologist burnout and how it impacts practice.

Olaparib/Radium-223 Combination Demonstrates Feasibility and Antitumor Activity in CRPC

Olaparib/Radium-223 Combination Demonstrates Feasibility and Antitumor Activity in CRPC

Tony Berberabe, MPH
June 4th 2025
Article

The combination of olaparib and radium-223 improved rPFS in castration-resistant prostate cancer without prior docetaxel treatment or with fewer than 20 bone metastases.

High Response Rates Seen with Fruquintinib Combo in HER2– Advanced Gastric/GEJ Cancer

High Response Rates Seen with Fruquintinib Combo in HER2– Advanced Gastric/GEJ Cancer

Kyle Doherty
June 4th 2025
Article

Fruquintinib plus chemotherapy and a PD-1 inhibitor elicited an ORR of 80.0% with all partial responses in patients with treatment-naïve gastric/GEJ cancer.